CADASIL: Diagnostic Workup and Management
In patients with CADASIL, aggressively counsel on smoking cessation and treat hypertension and other vascular risk factors, as this is the only proven beneficial intervention to reduce stroke risk 1.
Diagnostic Workup
Clinical Recognition
Suspect CADASIL in patients presenting with:
- Lacunar strokes typically in the 6th decade (though onset can be earlier)
- Migraine with aura (often the earliest manifestation)
- Progressive cognitive decline leading to dementia
- Pseudobulbar affect and mood disturbances
- Family history suggesting autosomal dominant inheritance (though de novo mutations occur)
Neuroimaging Findings
Brain MRI reveals characteristic patterns that should raise suspicion 1, 2:
- Confluent subcortical white matter disease in anterior temporal poles (highly specific)
- External capsule involvement bilaterally (key diagnostic feature)
- Periventricular and deep white matter hyperintensities
- Multiple lacunar infarcts in basal ganglia, thalamus, and pons
- Cerebral microbleeds (microhemorrhages)
Definitive Diagnosis
Genetic testing for NOTCH3 mutations on chromosome 19p13 is the gold standard 1, 2. This autosomal dominant condition involves cysteine-altering mutations in the NOTCH3 gene.
Skin biopsy can be reserved for cases where genetic testing is inconclusive, looking for granular osmiophilic material (GOM) around vascular smooth muscle cells on electron microscopy 3.
Management Strategy
Primary Stroke Prevention (Class I Recommendation)
The 2024 AHA/ASA guidelines provide the only Class I, evidence-based recommendation for CADASIL 1:
- Smoking cessation counseling (mandatory)
- Aggressive hypertension treatment
- Management of all modifiable vascular risk factors including:
- Diabetes control
- Hyperlipidemia management
- Weight management
Symptomatic Management
Since no disease-modifying therapy exists 1, 4, 5:
- Migraine management: Standard migraine therapies for symptom control
- Antiplatelet therapy: Consider aspirin for stroke prevention (though not specifically studied in CADASIL)
- Cognitive support: Neuropsychological evaluation and multidisciplinary cognitive care
- Mood disorders: Address depression, anxiety, and apathy with appropriate psychiatric care
Critical Pitfalls
Avoid anticoagulation without compelling indication - Given the presence of cerebral microbleeds and risk of hemorrhagic transformation, carefully weigh risks versus benefits of antithrombotic agents 1.
Do not assume standard stroke prevention strategies are proven - The roles of antiplatelet therapy, statins, and calcium channel blockers specifically for CADASIL stroke prevention remain unknown and unstudied 1.
Counsel patients and families on prognosis - CADASIL leads to progressive disability with accumulation of strokes, cognitive decline, and severe functional impairment typically by the 7th decade 6, 2, 5.
Genetic Counseling
Offer genetic counseling and testing to first-degree relatives, as this is an autosomal dominant condition with 50% transmission risk 6. Early identification allows for aggressive vascular risk factor modification before symptom onset.
Knowledge Gaps
The 2024 AHA/ASA guidelines explicitly acknowledge that disease-modifying therapies for CADASIL do not currently exist 1. Emerging research on NOTCH3-targeted therapies (exon skipping, gene silencing, immunotherapy) shows promise in preclinical studies but requires further investigation before clinical application 5.